Donaperminogene seltoplasmid is under clinical development by Helixmith and currently in Phase II for Intermittent Claudication. According to GlobalData, Phase II drugs for Intermittent Claudication does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Donaperminogene seltoplasmid LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Donaperminogene seltoplasmid overview
Donaperminogene seltoplasmid (VM-202) is under development for the treatment of critical limb ischemia, coronary artery disease, claudication. It is administered through intramuscular route (percutaneous transendocardial). It is a genomic-cDNA nucleic acid hybrid of human HGF gene, which expresses two isoforms of HGF, namely HGF and dHGF by way of alternative splicing. For construction of VM-202, HGF-X7 was inserted into pCK DNA vector. VM-202 consists of the proprietary pCK vector encoding the engineered hepatocyte growth factor gene. It was under development for the treatment angina pectoris, acute myocardial infarction, coronary artery disease, peripheral artery disease, diabetic ischemic foot ulcers and myocardial ischemia.
It was under development for the treatment of Charcot-Marie-tooth disease type I A, amyotrophic lateral sclerosis and painful diabetic peripheral neuropathy.
Helixmith overview
Helixmith is a biotechnology company that develops gene therapy products and natural nutraceuticals. The company’s pipeline products include Engensis (VM202), gene therapy drug that provides fundamental treatment through tissue regeneration, which treats diabetic peripheral neuropathy, amyotrophic lateral sclerosis, diabetic foot ulcer, claudication, charcot marie tooth disease and coronary artery disease. It also develops natural biometrical leveraging its expertise in natural medicine, health functional food and cosmetic products using botanical sources. The company operates in South Korea and the US. Helixmith is headquartered in Seoul, South Korea.
For a complete picture of Donaperminogene seltoplasmid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
